Plasma proteomic profiling and molecular clustering reveal immune‐defined prognostic subtypes in lung adenocarcinoma
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70231 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Ujjwal Neogi und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Systems Virology Lab, Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Proteomics, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Max-Planck-Gesellschaft, the German Center for Lung Research, Hessisches Ministerium für Wissenschaft und Kunst.
Abstract (Originalsprache)
Lung adenocarcinoma (LUAD) is a biologically and clinically heterogeneous disease that poses a major challenge for prognosis and treatment. In this study, we performed proteomic profiling in a cohort of 88 LUAD patients to identify molecular subgroups and investigate their clinical relevance. Unsupervised clustering of the proteomic data allowed us to identify two distinct patient groups with different demographic, clinical, and molecular characteristics. Cluster 1 consisted predominantly of older patients and showed increased expression of immune and inflammatory pathways, including significant enrichment of Tumor Necrosis Factor (TNF) and Toll‐like receptor signaling. This suggests a stronger innate immune response that may be associated with better disease control. In contrast, Cluster 2 was characterized by younger demographics, a higher proportion of female patients, and a greater frequency of smoking. This cluster showed reduced activation of immune‐related pathways and a significantly shorter time to disease recurrence, suggesting a more aggressive clinical course and poorer prognosis. The differential expression of immune pathways between clusters underscores the role of the tumor microenvironment in disease progression and response to treatment. Our results demonstrate the value of integrating proteomic and clinical data to identify biologically distinct LUAD subtypes. This molecular stratification can improve the understanding of tumor behavior and inform personalized treatment strategies. Thus, proteomic profiling is a promising tool to guide biomarker‐directed treatment of LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Systems Virology Lab, Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
- Institute for Lung Health (ILH), Justus Liebig University Giessen, Giessen, Germany.
- Max Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Member of the Cardio-Pulmonary Institute (CPI), Bad Nauheim, Germany.
- Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research (DZL), Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.
- Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.
- Institute of Translational Proteomics & Core Facility Translational Proteomics, Biochemical/Pharmacological Centre, University of Marburg, Marburg, Germany.
ORCID-Profile: Ujjwal Neogi, Rajkumar Savai
Förderung
- Max-Planck-Gesellschaft
- the German Center for Lung Research
- Hessisches Ministerium für Wissenschaft und Kunst
- Cardio-Pulmonary Institute
- Max Planck Society
- Institute for Lung Health (ILH)
- German Center for Lung Research
- Excellence Cluster Cardio-Pulmonary Institute
Zitieren
APA
Neogi, U., Ambikan, A. T., Turkowski, K., Schneider, M. A., Beutgen, V. M., Graumann, J., Winter, H., Bartkuhn, M., Seeger, W., Pullamsetti, S. S., & Savai, R. (2026). Plasma proteomic profiling and molecular clustering reveal immune‐defined prognostic subtypes in lung adenocarcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.70231
Vancouver
Neogi U, Ambikan AT, Turkowski K, Schneider MA, Beutgen VM, Graumann J, et al. Plasma proteomic profiling and molecular clustering reveal immune‐defined prognostic subtypes in lung adenocarcinoma. International Journal of Cancer. 2026. doi:10.1002/ijc.70231
BibTeX
@article{Neogi2026,
author = {Neogi, Ujjwal and Ambikan, Anoop T and Turkowski, Kati and Schneider, Marc A and Beutgen, Vanessa M and Graumann, Johannes and Winter, Hauke and Bartkuhn, Marek and Seeger, Werner and Pullamsetti, Soni S and Savai, Rajkumar},
title = {Plasma proteomic profiling and molecular clustering reveal immune‐defined prognostic subtypes in lung adenocarcinoma},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70231}
}
EUVIMED